DÄ internationalArchive18/2020Severe hemorrhage associated with oral anticoagulants

Original article

Severe hemorrhage associated with oral anticoagulants

A prospective observational study of the clinical course during treatment with vitamin K antagonists or direct oral anticoagulants

Dtsch Arztebl Int 2020; 117: 312-9. DOI: 10.3238/arztebl.2020.0312

Lindhoff-Last, E; Herrmann, E; Lindau, S; Konstantinides, S; Grottke, O; Nowak-Goettl, U; Lucks, J; Zydek, B; von Heymann, C; Birschmann, I; Sümnig, A; Beyer-Westendorf, J; Schellong, S; Meybohm, P; Greinacher, A

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

* Die beiden Autoren teilen sich die Letztautorenschaft.
Gerinnungszentrum und Studienzentrum, CardioAngiologisches Centrum Bethanien (CCB), Frankfurt/Main: Prof. Dr. med. Edelgard Lindhoff-Last
Institut für Biostatistik und mathematische Modellierung, Goethe-Universität, Frankfurt: Prof. Dr. rer. nat. Eva Herrmann
Abteilung für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinik Frankfurt/Main: Dr. med. Simone Lindau
Centrum für Thrombose und Hämostase (CTH), Universitätsmedizin der Johannes Gutenberg-Universität Mainz: Prof. Dr. med. Stavros Konstantinides
Abteilung für Anästhesiologie, RWTH Aachen Universitätsklinik, Aachen: PD Dr. med. Oliver Grottke
Institut für Klinische Chemie, Thrombose- und Hämostase-Behandlungszentrum, Universitätsklinik Kiel-Lübeck: Prof. Dr. med. Ulrike Nowak-Goettl
Studienzentrum des CardioAngiologischen Centrums Bethanien (CCB), Frankfurt/Main: Dr. phil. nat. Jessica Lucks, Dr. med. Barbara Zydek
Abteilung für Anästhesie, Intensivmedizin, Notfallmedizin und Schmerztherapie, Vivantes Klinikum, Berlin-Friedrichshain: Prof. Dr. med. Christian von Heymann
Institut für Laboratoriums- und Transfusionsmedizin, Herz- und Diabeteszentrum, Ruhr-Universität Bochum: PD Dr. med. Dr. rer. nat. Ingvild Birschmann
Abteilung für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald: Dr. med. Ariane Sümnig
Thrombosis Research Unit, Zentrum für Innere Medizin 1, Abteilung Hämatologie, Universitätsklinik Dresden und Department of Haematology and Oncology, Kings College London, England: PD Dr. med. Jan Beyer-Westendorf
Medizinische Abteilung 2, Städtisches Klinikum Dresden-Friedrichstadt: Prof. Dr. med. Sebastian Schellong
Abteilung für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinik Frankfurt und Abteilung für Anästhesie, Universitätsklinik Würzburg: Prof. Dr. med. Patrick Meybohm
Abteilung für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald: Prof. Dr. med. Andreas Greinacher
1.Patel MR, Mahaffey KW, Garg J, et al.: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–91 CrossRef MEDLINE
2.Connolly SJ, Ezekowitz MD, Yusuf S, et al.: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–51 CrossRef MEDLINE
3.Granger CB, Alexander JH, McMurray JJ, et al.: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–92 CrossRef MEDLINE
4.Einstein investigators, Bauersachs R, Berkowitz SD, et al.: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–510 CrossRef MEDLINE
5.Giugliano RP, Ruff CT, Braunwald E, et al.: Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–104 CrossRef MEDLINE
6.van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR: Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124: 1968–75 CrossRef MEDLINE
7.Ruff CT, Giugliano RP, Braunwald E, et al.: Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–62 CrossRef MEDLINE
8.Majeed A, Agren A, Holmstrom M, et al.: Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 2017; 130: 1706–12 CrossRef MEDLINE
9.Halvorsen S, Ghanima W, Fride Tvete I, et al.: A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother 2017; 3: 28–36 CrossRef MEDLINE PubMed Central
10.Xu Y, Schulman S, Dowlatshahi D, et al.: Direct oral anticoagulant- or warfarin-related major bleeding: characteristics, reversal strategies, and outcomes from a multicenter observational study. Chest 2017; 152: 81–91 CrossRef MEDLINE
11.Albaladejo P, Samama CM, Sie P, et al.: Management of severe bleeding in patients treated with direct oral anticoagulants: an observational registry analysis. Anesthesiology 2017; 127: 111–20 CrossRef MEDLINE
12.Green L, Tan J, Morris JK, et al.: A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study). Haematologica 2018; 103: 738–45 CrossRef MEDLINE PubMed Central
13.Kurogi R, Nishimura K, Nakai M, et al.: Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin. Neurology 2018; 90: e1143-9 CrossRef MEDLINE PubMed Central
14.Green L, Tan J, Antoniou S, et al.: Haematological management of major bleeding associated with direct oral anticoagulants – UK experience. Br J Haematol 2019; 185: 514–22 CrossRef MEDLINE
15.Piran S, Khatib R, Schulman S, et al.: Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. Blood Adv 2019; 3: 158–67 CrossRef MEDLINE PubMed Central
16.Steffel J, Verhamme P, Potpara TS, et al.: The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39: 1330–93 CrossRef MEDLINE
17.Dager WE, Roberts AJ, Nishijima DK: Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants. Thromb Res 2019; 173: 71–6 CrossRef MEDLINE
18.Lindhoff-Last E: Direct oral anticoagulants (DOAC) – management of emergency situations. Hämostaseologie 2017; 37: 257–66 CrossRef
19.Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis: Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692–4 CrossRef MEDLINE
20.Becattini C, Franco L, Beyer-Westendorf J, et al.: Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. Int J Cardiol 2017; 227: 261–6 CrossRef MEDLINE